Serum semicarbazide-sensitive amine oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients.
Garpenstrand
Håkan
H
Department of Neuroscience, Unit of Pharmacology, Uppsala University, 751 85 Uppsala, Sweden.
Bergqvist
Michael
M
Brattström
Daniel
D
Larsson
Anders
A
Oreland
Lars
L
Hesselius
Patrik
P
Wagenius
Gunnar
G
D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology; D006631:Amine Oxidase (Copper-Containing) / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000097:blood*; D006801:Humans; D007118:Immunoassay; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008297:Male; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D011379:Prognosis; D011854:Radiochemistry; D016019:Survival Analysis; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D042461:Vascular Endothelial Growth Factor A; D016222:Fibroblast Growth Factor 2; D006631:Amine Oxidase (Copper-Containing)